Vertex Entered into an Exclusive Four-Year Research Collaboration with Verve Therapeutics to Develop an In Vivo Gene Editing Program for Liver Disease
Shots:
- Verve to receive $60M up front incl. $35M in equity investment & is also eligible to receive an additional fee of ~$66M, $340M in development and commercial milestones along with royalties on net sales for any products resulting from the collaboration
- Verve will accelerate the discovery, research, and preclinical development of a novel in vivo gene editing program for the target of interest with all program costs funded by Vertex. Vertex will lead the development, manufacturing, and commercialization of the program resulting from Verve's research efforts.
- The agreement expands Verve's gene editing capabilities and pipeline to develop in vivo gene editing therapies for serious diseases
Ref: Vertex | Image: Vertex
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
